Innate Pharma and IFLI Partner to Advance IPH6501 in Follicular Lymphoma
核心洞察
Innate Pharma and the Institute for Follicular Lymphoma Innovation (搜索) (IFLI) have entered into an agreement to clinically study IPH6501 in follicular lymphoma (搜索).
IFLI will invest an initial $3 million in Innate shares, with potential additional investments up to $4.9 million based on milestone achievements.
The collaboration will expand Innate’s Phase 1/2 trial of IPH6501 to include patients with relapsed/refractory follicular lymphoma (搜索).
Marseille, France & Diamond Bar, CA – Innate Pharma SA and the Institute for Follicular Lymphoma Innovation (搜索) (IFLI) have announced a collaboration to advance the clinical development of IPH6501, Innate's anti-CD20 (搜索) ANKET® (Antibody-based NK cell Engager Therapeutics) in patients with follicular lymphoma (搜索) (FL). The partnership includes an investment of up to $7.9 million from IFLI to support the ongoing Phase 1/2 trial of IPH6501.
Financial Details of the Agreement
Under the terms of the agreement, IFLI will make an initial investment of $3 million into new shares of Innate Pharma at a price of €1.56 per share, representing 2.26% of Innate's share capital. Furthermore, IFLI may invest up to an additional $4.9 million into new shares of Innate, contingent upon the achievement of specific milestones in the clinical development of IPH6501.
Clinical Trial Expansion
The collaboration will facilitate the expansion of Innate Pharma’s ongoing Phase 1/2, open-label, multicenter trial to include patients with relapsed/refractory (R/R) FL. This trial is designed to evaluate the safety, tolerability, and preliminary antineoplastic activity of IPH6501 in patients with relapsed and/or refractory CD20 (搜索)-expressing Non-Hodgkin Lymphoma (搜索).
Expert Commentary
“At Innate Pharma, we are deeply committed to advancing innovative research and development to improve outcomes for patients with non-Hodgkin lymphoma (搜索), and this agreement with the Institute for Follicular Lymphoma Innovation (搜索) will contribute to our mission to bring forward therapeutic options that address critical needs and enhance the quality of life for those affected by this challenging disease,” said Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma.
Dr. Michel Azoulay, Chief Medical Officer of IFLI, added, “IFLI believes IPH6501 holds great promise for improving patient outcomes in non-Hodgkin lymphomas, including follicular lymphoma (搜索). We are delighted to support Innate and the investigation of IPH6501 in FL patients and, upon milestone achievement, to continue to support future clinical development of IPH6501 in FL. This collaboration provides a model for how IFLI’s philanthropic investments can catalyze FL development.”
About IPH6501
IPH6501 is Innate Pharma's proprietary anti-CD20 (搜索) ANKET® therapeutic. ANKET® is a platform designed to enhance natural killer (NK) cell activity to target and destroy cancer cells. By targeting CD20, a protein expressed on the surface of lymphoma cells, IPH6501 aims to provide a novel therapeutic approach for patients with Non-Hodgkin Lymphoma (搜索), including follicular lymphoma (搜索).
About Follicular Lymphoma
Follicular lymphoma (搜索) is a type of non-Hodgkin lymphoma (搜索) characterized by the slow growth of tumors. While initial treatment can be effective, many patients experience relapse, highlighting the need for new therapeutic options. The Institute for Follicular Lymphoma Innovation (搜索) (IFLI) is dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL).